

THE LIVER WEEK 2024



June 27-29, 2024 | Walkerhill, Seoul, Korea

Towards Precision Medicine in Practice and Research of Hepatology

Plenary Presentation 1 [Friday, June 28, 2024, 11:40-12:40]

Time	Abstract No.	Subject	Presenting Author	Institution/Affiliation	Corresponding Author	Institution/Affiliation
11:40-11:55	PS 1-1 387	Transarterial Radioembolization versus Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma with Portal Vein Thrombosis	Youngsu Park	Seoul National University	Yoon Jun Kim	Seoul National University
11:55-12:10	PS 1-2 467	LI-RADS Imaging Diagnosis of Hepatocellular Carcinoma in Noncirrhotic Patients with Chronic Hepatitis C: A Multicenter Development and Validation Cohort	Ha Il Kim	Hanyang University	Ju Hyun Shim	University of Ulsan
12:10-12:25	PS 1-3 719	Anatomical Risk Factors for Portal Vein Complications Following Right Hepatectomy in Living Donors: Analysis of Results from 4720 Cases	Young-In Yoon	University of Ulsan	Dong-Hwan Jung	University of Ulsan
12:25-12:40	PS 1-4 298	Persistent Systemic Inflammation Is Important Driver of Acute-on-Chronic Liver Failure and Organ Failure Development	Do Seon Song	The Catholic University of Korea	U Im Chang	The Catholic University of Korea

Plenary Presentation 2 [Saturday, June 29, 2024, 11:20-12:20]

Time	Abstract No.	Subject	Presenting Author	Institution/Affiliation	Corresponding Author	Institution/Affiliation
11:20-11:35	PS 2-1 99	Merlin-TAZ Pathway by miR-4449 Regulates Fibrosis Progression in MASH	Young-Sun Lee	Korea University	Young-Sun Lee	Korea university
11:35-11:50	PS 2-2 498	Cardiovascular Risk from Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes	Han Ah Lee	Chung-Ang University	Seung Up Kim	Yonsei University
11:50-12:05	PS 2-3 573	AI-Assisted Intraoperative Navigation for Safe Right Liver Mobilization during Pure Laparoscopic Donor Right Hepatectomy	Namkee Oh	Sungkyunkwan University	Gyu-Seong Choi	Sungkyunkwan University
12:05-12:20	PS 2-4 128	EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization (TACE) Combined with Durvalumab (D) with or without Bevacizumab (B) in Participants with Unresectable Hepatocellular Carcinoma (uHCC) Eligible for Embolization	Jeong Heo	Pusan National University	Jeong Heo	Pusan National University